AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33188155 — intervention group
Group type: EXPERIMENTAL
Intervention: HERMES, DAWN, DEFUSE 3 trials (pivotal EVT trials)
Number of subjects: 105
Study 33188155 — intervention group
Group type: COMPARATOR
Intervention: Medical management (MM)
Number of subjects: 105
Study 32735782 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol 400 mg
Number of subjects: 82
Study 32735782 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol 800 mg
Number of subjects: 82
Study 32735782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 32914666 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal Inspiratory Pressure (MIP)
Number of subjects: 61
Study 33800775 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality therapy and Mirror Therapy (MT)
Number of subjects: 59
Study 33800775 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 59
Study 32229194 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 15 mg/kg
Number of subjects: 60
Study 32229194 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study 35803896 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 80
Study 35803896 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant medication (ADM)
Number of subjects: 80
Study 34365776 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin or sulfonylurea/metformin combination (Group 1)
Number of subjects: 264
Study 34365776 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinedione combination (Group 2)
Number of subjects: 264
Study 34365776 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipeptidyl peptidase‐4 inhibitor (gemigliptin) combination (Group 3)
Number of subjects: 264
Study 34365776 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium‐glucose cotransporter 2 inhibitor (empagliflozin) combination (Group 4)
Number of subjects: 264
Study 34365776 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 264
Study 35484019 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) intervention
Number of subjects: 34
Study 35484019 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 34
Study 34112708 — intervention group
Group type: COMPARATOR
Intervention: fotemustine
Number of subjects: 80
Study 34112708 — intervention group
Group type: COMPARATOR
Intervention: ipilimumab plus fotemustine
Number of subjects: 80
Study 34112708 — intervention group
Group type: EXPERIMENTAL
Intervention: ipilimumab plus nivolumab
Number of subjects: 80
Study 35988951 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19-induced stress
Number of subjects: 1188
Study 35988951 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19-induced loneliness
Number of subjects: 1188
Study 35988951 — intervention group
Group type: EXPERIMENTAL
Intervention: No limitation of physical interactions due to COVID-19
Number of subjects: 1188
Study 35988951 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased use of a food bank
Number of subjects: 1188
Study 35988951 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative change in financial situation
Number of subjects: 1188
Study 32737054 — intervention group
Group type: EXPERIMENTAL
Intervention: dDAVP oral lyophilisate administered sublingually as a single dose after a water load.
Number of subjects: 0
Study 32737054 — intervention group
Group type: EXPERIMENTAL
Intervention: dDAVP oral lyophilisate
Number of subjects: 0
Study 33947446 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma (CCP) approximately 500 mL
Number of subjects: 1200
Study 33947446 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1200
Study 35762831 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer data benchmarking report intervention
Number of subjects: 489
Study 35762831 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 489
Study 33535830 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-handed jaw thrust (n = 46)
Number of subjects: 92
Study 33535830 — intervention group
Group type: COMPARATOR
Intervention: Conventional intubation with sham jaw thrust (n = 46)
Number of subjects: 92
Study 35315323 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (QIV)
Number of subjects: 2000
Study 35315323 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 2000
Study 34889041 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep mode CO2 fractional laser (n=15)
Number of subjects: 30
Study 34889041 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid mode CO2 fractional laser (n=15)
Number of subjects: 30
Study 34889041 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion mode CO2 fractional laser (n=30)
Number of subjects: 30
Study 33369704 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib 500 mg twice daily
Number of subjects: 9
Study 33369704 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg every 21 days
Number of subjects: 9
Study 33369704 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg twice daily
Number of subjects: 9
Study 33369704 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib (various doses) with Bevacizumab
Number of subjects: 9
Study 32715754 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 0
Study 32715754 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 0
Study 33896233 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based palliative care
Number of subjects: 25
Study 33896233 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for improving home-based palliative care access
Number of subjects: 25
Study 35767039 — intervention group
Group type: EXPERIMENTAL
Intervention: Early weight-bearing mobilization accelerated rehabilitation (AR group)
Number of subjects: 68
Study 35767039 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation (TR group)
Number of subjects: 68
Study 33955610 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge eating frequency assessed on a recall basis for 4 weeks before and during lockdown
Number of subjects: 0
Study 33955610 — intervention group
Group type: EXPERIMENTAL
Intervention: General ED pathology and depressive symptoms
Number of subjects: 0
Study 33955610 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion regulation strategy (reappraisal) and sense of coherence
Number of subjects: 0
Study 32236828 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab/pertuzumab
Number of subjects: 1230
Study 32236828 — intervention group
Group type: EXPERIMENTAL
Intervention: TDM1
Number of subjects: 1230
Study 36203695 — intervention group
Group type: EXPERIMENTAL
Intervention: Thirsty for a Smile intervention (home delivery of bottled water and dietary counseling)
Number of subjects: 22
Study 32438988 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding events
Number of subjects: 684
Study 32438988 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding within the first 2 days of hospitalization
Number of subjects: 684
Study 32438988 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding
Number of subjects: 684
Study 32438988 — intervention group
Group type: EXPERIMENTAL
Intervention: Active mechanical support (extracorporeal membrane oxygenation or Impella)
Number of subjects: 684
Study 33714479 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural mobilization (NM) in addition to standard rehabilitation
Number of subjects: 24
Study 33714479 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (CTRL)
Number of subjects: 24
Study 35761328 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial ablation plus LNG-IUS
Number of subjects: 0
Study 35761328 — intervention group
Group type: COMPARATOR
Intervention: Endometrial ablation alone
Number of subjects: 0
Study 34585591 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive coronary angiography (within 12 hours)
Number of subjects: 2147
Study 34585591 — intervention group
Group type: COMPARATOR
Intervention: Standard invasive coronary angiography (48-72 hours)
Number of subjects: 2147
Study 32757652 — intervention group
Group type: EXPERIMENTAL
Intervention: Early planned mobilization in the first 2 days after surgery
Number of subjects: 92
Study 32757652 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care only (Control)
Number of subjects: 92
Study 36474201 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Skills Training Group (SSTG)
Number of subjects: 128
Study 36474201 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational Control Intervention
Number of subjects: 128
Study 34634163 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical finasteride
Number of subjects: 458
Study 34634163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study 34634163 — intervention group
Group type: COMPARATOR
Intervention: Oral finasteride
Number of subjects: 458
Study 33034559 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) coaching intervention
Number of subjects: 89
Study 35500019 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing about future teaching-related events (n = 67)
Number of subjects: 129
Study 35500019 — intervention group
Group type: COMPARATOR
Intervention: Control group writing about a walk in a forest and a city park (n = 62)
Number of subjects: 129
Study 33127365 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise decrease in NCPAP pressure to 3 cm H2O (wean group)
Number of subjects: 226
Study 33127365 — intervention group
Group type: COMPARATOR
Intervention: Immediate cessation of NCPAP at 5 cm H2O (control group)
Number of subjects: 226
Study 34241947 — intervention group
Group type: EXPERIMENTAL
Intervention: CoCr‐DCS
Number of subjects: 401
Study 34241947 — intervention group
Group type: COMPARATOR
Intervention: Propensity-matched cohort (SS‐DCS)
Number of subjects: 401
Study 34241947 — intervention group
Group type: COMPARATOR
Intervention: Propensity-matched cohort (SS‐BMS)
Number of subjects: 401
Study 33926704 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of antithrombin III (n = 64)
Number of subjects: 141
Study 33926704 — intervention group
Group type: COMPARATOR
Intervention: Non-administration of antithrombin III (n = 77)
Number of subjects: 141
Study 32105889 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-stage ERCP plus laparoscopic cholecystectomy (group A, n=39)
Number of subjects: 119
Study 32105889 — intervention group
Group type: EXPERIMENTAL
Intervention: ERCP plus laparoscopic cholecystectomy in the same hospitalization (group B, n=43)
Number of subjects: 119
Study 32105889 — intervention group
Group type: COMPARATOR
Intervention: Delayed cholecystectomy after ERCP (group C, n=37)
Number of subjects: 119
Study 35224875 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Glissonian pedicle approach hemihepatectomy (LGAH)
Number of subjects: 190
Study 34932660 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucoadhesive patches delivering lidocaine and prilocaine hydrochlorides (1:1, 30 mg/patch)
Number of subjects: 58
Study 33579279 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia Care Mapping (DCM) training
Number of subjects: 27
Study 33579279 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia Care Mapping (DCM) implementation
Number of subjects: 27
Study 33579279 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustaining DCM
Number of subjects: 27
Study 32638027 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical exertion
Number of subjects: 1246
Study 32638027 — intervention group
Group type: EXPERIMENTAL
Intervention: Low social support
Number of subjects: 1246
Study 32638027 — intervention group
Group type: EXPERIMENTAL
Intervention: Working with arms above shoulder level
Number of subjects: 1246
Study 32638027 — intervention group
Group type: EXPERIMENTAL
Intervention: Total incident UEMSD
Number of subjects: 1246
Study 33634665 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-While-Incarcerated (TWI)
Number of subjects: 0
Study 33634665 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient Treatment (OP)
Number of subjects: 0
Study 33634665 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-Control (WC)
Number of subjects: 0
Study 36161136 — intervention group
Group type: EXPERIMENTAL
Intervention: FCHV-delivered intervention for 12 months
Number of subjects: 690
Study 36161136 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 690
Study 36161136 — intervention group
Group type: EXPERIMENTAL
Intervention: FCHV-delivered intervention
Number of subjects: 690
Study 32050695 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic whole-body strength training including 3 x 10 squat jumps with WB-EMS (EG)
Number of subjects: 30
Study 32050695 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump training without EMS (TG)
Number of subjects: 30
Study 32050695 — intervention group
Group type: COMPARATOR
Intervention: Control group performing daily soccer routine (CG)
Number of subjects: 30
Study 616726149 — intervention group
Group type: EXPERIMENTAL
Intervention: Mist fan
Number of subjects: 35
Study 616726149 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling towel
Number of subjects: 35
Study 616726149 — intervention group
Group type: COMPARATOR
Intervention: Passive-cooling (no intervention) control
Number of subjects: 35
Study 36107530 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevel facing dorsal direction (Group D)
Number of subjects: 2
Study 36107530 — intervention group
Group type: COMPARATOR
Intervention: Bevel facing left (Group L)
Number of subjects: 2
Study 36107530 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2
Study 33261542 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (75g in 200mL solution)
Number of subjects: 16
Study 33261542 — intervention group
Group type: COMPARATOR
Intervention: Glucose (75g in 200mL solution)
Number of subjects: 16
Study 32316801 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucovorin rescue at 24 hours after HDMTX infusion
Number of subjects: 98
Study 32316801 — intervention group
Group type: COMPARATOR
Intervention: Leucovorin rescue at 18 hours after HDMTX infusion
Number of subjects: 98
Study 32748165 — intervention group
Group type: EXPERIMENTAL
Intervention: Double continuous suture
Number of subjects: 100
Study 32748165 — intervention group
Group type: COMPARATOR
Intervention: Interrupted suture
Number of subjects: 100
Study 36204974 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT (Cognitive Processing Therapy)
Number of subjects: 80
Study 36204974 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT combined with cognitive rehabilitation (SMART‐CPT)
Number of subjects: 80
Study 33508496 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual-reality exposure in multiple contexts
Number of subjects: 30
Study 33508496 — intervention group
Group type: COMPARATOR
Intervention: Virtual-reality exposure in single context
Number of subjects: 30
Study 32448935 — intervention group
Group type: EXPERIMENTAL
Intervention: No episiotomy (study group)
Number of subjects: 676
Study 32448935 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 676
Study 36151277 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing and flossing (TB + DF)
Number of subjects: 75
Study 36151277 — intervention group
Group type: COMPARATOR
Intervention: Toothbrushing alone
Number of subjects: 75
Study 32882429 — intervention group
Group type: EXPERIMENTAL
Intervention: MG probing plus post‐procedural topical sulfacetamide/prednisolone ointment (Blephamide®)
Number of subjects: 42
Study 32882429 — intervention group
Group type: EXPERIMENTAL
Intervention: MG probing plus post‐procedural lubricating ointment (GenTeal)
Number of subjects: 42
Study 32882429 — intervention group
Group type: COMPARATOR
Intervention: Sham probing plus GenTeal ointment
Number of subjects: 42
Study 616627928 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based asthma intervention (4 visits over 1 year)
Number of subjects: 590
Study 616627928 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 590
Study 33878763 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm A (exclusive consideration of carbohydrate content)
Number of subjects: 26
Study 33878763 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm B (high-dose algorithm considering additional insulin for fat protein units)
Number of subjects: 26
Study 33878763 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm C (low-dose algorithm considering additional insulin for fat protein units)
Number of subjects: 26
Study 33878763 — intervention group
Group type: COMPARATOR
Intervention: Control (not considering fat-protein content)
Number of subjects: 26
Study 33232639 — intervention group
Group type: COMPARATOR
Intervention: MICT (5×30 min/week, 35%-50% HRR)
Number of subjects: 29
Study 33232639 — intervention group
Group type: COMPARATOR
Intervention: 1HIIT (3×17 min/week incl. 4 min @80%-90% HRR)
Number of subjects: 29
Study 33232639 — intervention group
Group type: COMPARATOR
Intervention: 4HIIT (3×38 min/week incl. 4×4 min @80%-90% HRR)
Number of subjects: 29
Study 33232639 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire group (all interventions combined)
Number of subjects: 29
Study 32710447 — intervention group
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA
Number of subjects: 38
Study 32710447 — intervention group
Group type: COMPARATOR
Intervention: onabotulinumtoxinA
Number of subjects: 38
Study 35933320 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-smoking intervention (ASI)
Number of subjects: 72
Study 35933320 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ASI)
Number of subjects: 72
Study 34426836 — intervention group
Group type: EXPERIMENTAL
Intervention: AHRE duration >6 min to ≤6 h
Number of subjects: 2718
Study 34426836 — intervention group
Group type: EXPERIMENTAL
Intervention: AHRE duration >6 h
Number of subjects: 2718
Study 34426836 — intervention group
Group type: EXPERIMENTAL
Intervention: AHRE duration >6 min
Number of subjects: 2718
Study 34426836 — intervention group
Group type: EXPERIMENTAL
Intervention: AHRE duration >24 h
Number of subjects: 2718
Study 35443062 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib with platinum-docetaxel
Number of subjects: 52
Study 35443062 — intervention group
Group type: COMPARATOR
Intervention: Placebo with platinum-docetaxel
Number of subjects: 52
Study 35443062 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib with chemotherapy
Number of subjects: 52
Study 32631157 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 273
Study 32631157 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 273
Study 32631157 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (after excluding stroke mimics)
Number of subjects: 273
Study 32631157 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (after excluding stroke mimics)
Number of subjects: 273
Study 32877244 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-RADS category 2 lesions
Number of subjects: 110
Study 32877244 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-RADS category 3 lesions
Number of subjects: 110
Study 32877244 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-RADS category 4 lesions
Number of subjects: 110
Study 32877244 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-RADS category 5 lesions
Number of subjects: 110
Study 32877244 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-RADS category 1 lesions
Number of subjects: 110
Study 32877244 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal multiparametric MRI findings (PI-RADS 1)
Number of subjects: 110
Study 35542997 — intervention group
Group type: EXPERIMENTAL
Intervention: Piromelatine 20 mg
Number of subjects: 371
Study 35542997 — intervention group
Group type: EXPERIMENTAL
Intervention: Piromelatine
Number of subjects: 371
Study 35542997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study 32240527 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg every 2 weeks)
Number of subjects: 0
Study 34231490 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term antithyroid drug therapy (LTADT; >24 months of treatment)
Number of subjects: 0
Study 34737296 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 for 24 weeks
Number of subjects: 130
Study 34737296 — intervention group
Group type: COMPARATOR
Intervention: Peg-IFN-α-2b therapy
Number of subjects: 130
Study 32700060 — intervention group
Group type: COMPARATOR
Intervention: Digital human with no face and neutral voice
Number of subjects: 185
Study 32700060 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital human with no face
Number of subjects: 185
Study 32700060 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital human with no face and emotional voice
Number of subjects: 185
Study 32700060 — intervention group
Group type: COMPARATOR
Intervention: Digital human with neutral face
Number of subjects: 185
Study 32700060 — intervention group
Group type: COMPARATOR
Intervention: Digital human with emotional face
Number of subjects: 185
Study 36027564 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial blood-pressure target of 77 mm Hg
Number of subjects: 789
Study 36027564 — intervention group
Group type: COMPARATOR
Intervention: Mean arterial blood-pressure target of 63 mm Hg
Number of subjects: 789
Study 33309875 — intervention group
Group type: EXPERIMENTAL
Intervention: Maze + LA reduction group (n=70)
Number of subjects: 140
Study 33309875 — intervention group
Group type: COMPARATOR
Intervention: Maze group (n=70)
Number of subjects: 140
Study 35318365 — intervention group
Group type: EXPERIMENTAL
Intervention: GWS + MIT
Number of subjects: 60
Study 35318365 — intervention group
Group type: EXPERIMENTAL
Intervention: GWS + CIT
Number of subjects: 60
Study 35318365 — intervention group
Group type: EXPERIMENTAL
Intervention: PUI + MIT
Number of subjects: 60
Study 35318365 — intervention group
Group type: EXPERIMENTAL
Intervention: PUI + CIT
Number of subjects: 60
Study 32122726 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure of the extraction socket with a mucoperiosteal flap (group A)
Number of subjects: 77
Study 32122726 — intervention group
Group type: COMPARATOR
Intervention: Application of platelet-rich fibrin (PRF) without subsequent primary closure (group B)
Number of subjects: 77